BusinessCRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-ThalassemiaBy Nasdaq OMXNov 21, 2016, 1:00 PM UTC
BusinessCRISPR Therapeutics to Present at the Stifel 2016 Healthcare ConferenceBy Nasdaq OMXNov 8, 2016, 1:00 PM UTC
BusinessCRISPR Therapeutics Announces Pricing of Initial Public OfferingBy Nasdaq OMXOct 19, 2016, 2:00 AM UTC
